Hikma Pharmaceuticals Public annual gross profit
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Gross Profit Growth & History (HIK)
Hikma Pharmaceuticals Public's gross profit was $1.44B for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.44B | $26.0M | +1.84% |
| 2024 | 2024-12-31 | $1.42B | $25.0M | +1.80% |
| 2023 | 2023-12-31 | $1.39B | $152.0M | +12.28% |
| 2022 | 2022-12-31 | $1.24B | −$63.0M | −4.84% |
| 2021 | 2021-12-31 | $1.30B | $100.0M | +8.33% |
| 2020 | 2020-12-31 | $1.20B | — | — |
Hikma Pharmaceuticals Public gross profit trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's gross profit increased from $1.20B to $1.44B, a change of $240.0M.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
reported and calculated gross profit
TickerStat uses gross profit reported in company official filings when available. Otherwise, it calculates gross profit as reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...